Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, CPI, and CDK4/6 ...
Volastra Therapeutics, a clinical-stage oncology company pioneering therapies targeting chromosomal instability (CIN), today ...
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...
Biomarkers identified in BriaCell’s Phase 2 study are showing similar and encouraging trends in the ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast cancer (MBC) No new safety or ...
Plasma protein biomarkers linked to urological cancer risk reveal causal targets and potential therapies through Mendelian ...
Early detection and prevention of cancer can save lives, but current tools often fall short because of suboptimal accuracy and limited accessibility. The Fred Hutch Cancer Center aims to change that ...
Hosted on MSN
Making cancer trials smarter with better endpoints
Cancer clinical trials are moving toward endpoints that better capture meaningful patient outcomes. Updated FDA guidance and expert collaborations are refining how survival, disease progression, and ...
Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) from short-term survivors (<1year) OS Therapies Inc. (NYSE:OSTX) Leveraging the power ...
AT-108 induces powerful, personalized anti-cancer responses by forcing tumor cells to present their antigens to the immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results